A Phase I Study of AEB071 in Patients with CD79-Mutant Diffuse Large B-Cell Lymphoma

Full Title
An Open-Label, Single-arm, Phase I study of AEB071 (a Protein Kinase C Inhibitor) in Patients with CD79-mutant Diffuse Large B-Cell Lymphoma

The purpose of this study is to find the highest dose of an investigational drug called AEB071 that can be given safely in patients with diffuse large B-cell lymphoma (DLBCL) that contains a mutated form of the CD79 gene and has returned despite prior chemotherapy. AEB071 works by inhibiting protein kinase C, an enzyme which fuels cancer growth. AEB071 is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have DLBCL that has returned despite prior chemotherapy and contains a mutated form of the CD79 gene.
  • At least 2 weeks must have passed since completion of prior chemotherapy (4 weeks since receipt of biologic drugs, such as antibodies) and entry into the study.
  • This study is open to patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. John Gerecitano at 212-639-3748.

Lymphoma: Non-Hodgkin's Lymphoma
Related Diseases